alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 201
Editorial Note: Nomenclature changes to part 201 appear at 69 FR 13717, Mar. 24, 2004.

§ 201.120 Prescription chemicals and other prescription components. A drug prepared, packaged, and primarily sold as a prescription chemical or other component for use by registered pharmacists in compounding prescriptions or for dispensing in dosage unit form upon prescriptions shall be exempt from section 502(f)(1) of the act if all the following conditions are met: ( a ) The drug is an official liquid acid or official liquid alkali, or is not a liquid solution, emulsion, suspension, tablet, capsule, or other dosage unit form; and
( b ) The label of the drug bears: ( 1 ) The statement “For prescription compounding”; and
( 2 ) If in substantially all dosage forms in which it may be dispensed it is subject to section 503(b)(1) of the act, the statement “Rx only”; or
( 3 ) If it is not subject to section 503(b)(1) of the act and is by custom among retail pharmacists sold in or from the interstate package for use by consumers, “adequate directions for use” in the conditions for which it is so sold. *Provided, however,* That the information referred to in paragraph (b)(3) of this section may be contained in the labeling on or within the package from which it is to be dispensed.
( c ) This exemption shall not apply to any substance intended for use in compounding which results in a new drug, unless an approved new-drug application covers such use of the drug in compounding prescriptions.
[40 FR 13998, Mar. 27, 1975, as amended at 67 FR 4906, Feb. 1, 2002]
I 

118TH CONGRESS 

2D SESSION H. R. 7384 

To amend the Federal Food, Drug, and Cosmetic Act to extend the authority 

of the Secretary of Health and Human Services to issue priority review 

vouchers to encourage treatments for rare pediatric diseases. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 15, 2024 

Mr. MCCAUL (for himself, Ms. ESHOO, Mr. BILIRAKIS, Ms. BARRAGA ́N, Mrs. 

TRAHAN, and Mr. BURGESS) introduced the following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To amend the Federal Food, Drug, and Cosmetic Act to 

extend the authority of the Secretary of Health and 

Human Services to issue priority review vouchers to encourage treatments for rare pediatric diseases. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Creating Hope Reau5 thorization Act of 2024’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7384 IH

1 SEC. 2. EXTENSION OF AUTHORITY TO ISSUE PRIORITY RE2 VIEW VOUCHERS TO ENCOURAGE TREAT3 MENTS FOR RARE PEDIATRIC DISEASES. 

4 Section 529(b)(5) of the Federal Food, Drug, and 

5 Cosmetic Act (21 U.S.C. 360ff(b)(5)) is amended— 

6 (1) by striking ‘‘September 30, 2024’’ each 

7 place it appears and inserting ‘‘September 30, 

8 2028’’; and 

9 (2) in subparagraph (B), by striking ‘‘Sep10 tember 30, 2026’’ and inserting ‘‘September 30, 

11 2030’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
### PREFLIGHT CHECKLIST

 **AREA OF FLIGHT ................................**  **.. CHECK FOR HAZARDS**   **BATTERY LEVEL S**  **................................ CHECK** **(A/C, REMOTE, AND TABLET)**   **PROPS ................................**  **....................... CHECK AND SECURE**   **LENS FILTER**  **................................ ..........**  **CHECK**  **REMOTE CONTROL ..............................**  **ON**  **TABLET IN AIRPLANE MODE ............**  **CONFIRM**  **FLIGHT MOD E SWITCH**  **...................... P** 

**– Mode**   **A/C POWER ................................**  **.............. O** **N**  **DJI PILOT APP ................................**  **........ ON AND**  **CONNECTED** o **ON SCREEN FLIGHT MODE**  **....... CONFIRM**  **P -** **ATTI & SAFE TO FLY**  o **A/C BATTERY STATUS ..................**  **CHECKED** o **FREQUENCIES.........................CHECK**  **COMPASS ................................**  **................. CALIBRAT** **E**  **GPS SIGNAL ................................**  **............ AQUIRED (FLASHING GREEN)**   **HOME POINT ................................**  **.......... SET**   **GI MBAL MODE**  **................................ ......**  **SET**  **CAMERA SETTINGS ..............................**  **SET**  **AREA ................................**  **......................... CLEAR**   **MOTORS ................................**  **................... ARM**   **FLIGHT CONTROLS**  **.............................. CHECKED**   **TAKEOFF ................................**  **................. ACCOMPLISH**   **LANDING GEAR ................................**  **..... UP** 



### POSTFLIGHT CHECKLIST

 **A/C ................................**  **.............................. DISARM**   **A/C POWER ................................**  **.............. OFF**   **REMOTE POWER ................................**  **... OFF**   **PROPS ................................**  **....................... REMOVE / INSPECT**   **MOTORS ................................**  **................... CHECK FREE AND**  **CLEAR**  **AIRFRAME ................................**  **............... INSPECT**
**Exhibit32**

**CERTIFICATIONPURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED**

**PURSUANTTO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The certifications set forth below are hereby submitted to the Securitiesand Exchange Commission pursuant to, and solely for the purpose of complyingwith, Section 1350 of Chapter 63 of Title 18 of the United States Code inconnection with the filing on the date hereof with the Securities and ExchangeCommission of the Quarterly Report on Form 10-Q of the Company for thequarter ended March 31, 2007.

Eachof the undersigned hereby certifies in his capacity as an officer of CitizensBancshares Corporation and subsidiaries (the “Company”) that, to his knowledgeon the date of this certification, the Quarterly Report of the Company on Form10-Q for the period ended March 31, 2007 fully complies with the requirementsof Section 13(a) of the Securities Exchange Act of 1934 and that theinformation contained in such report fairly presents, in all material respects,the financial condition of the Company at the end of such period and theresults of operations of the Company for such period.

 
| Date: May 15, 2007 |   | By:                                   | /s/ James E. Young |   |
|--------------------|--------|---------------------------------------|--------------------|--------|
|               |   | James E. Young                        |
|               |   | President and Chief Executive Officer |
|               |   |                                  |
|               |   |                                  |
| Date: May 15, 2007 |   | By:                                   | /s/ Cynthia N. Day |   |
|               |   | Cynthia N. Day                        |
|               |   | Senior Executive Vice President and   |
|               |   | Chief Operating Officer               |
|               |   |                                  |
|               |   |                                  |
| Date: May 15, 2007 |   | By:                                   | /s/ Samuel J. Cox  |   |
|               |   | Samuel J. Cox                         |
|               |   | Senior Vice President and             |
|               |   | Chief Financial Officer               |
|                    |        |                                       |                    |        |  |  |

 

1

----
# STATEOFLOUISIANA



# COURTOFAPPEAL,

# FIRSTCIRCUIT

DEVON ENERGY PRODUCTION NO. 

### 2022 CW 0349 COMPANY, L. P. VERSUS 

### LOUISIANA DEPARTMENT OF NATURAL RESOURCES AND THOMAS HARRIS, 

### IN HIS CAPACITY AS SECRETARY OF THE LOUISIANA DEPARTMENT OF NATURAL RESOURCES 

### JULY 05, 2022

In Re: Devon 

## Energy Production 

## Company, L. P., 

### applying for supervisory writs, 

### 19th Judicial District Court, 

### Parish of East Baton Rouge, No. 

### 699354.

BEFORE: McCLENDON, WELCH, AND HESTER, JJ.



### WRIT GRANTED WITH ORDER. The trial 

### court's March 23, 2022 ruling 

## denying the motion 

### for summary 

### judgment 

## filed by Devon 

### Energy Production 

## Company, LP, 

### is 

## hereby vacated. When the trial court 

### originally 

### issued the alternative writ of mandamus order, the court ordered defendants to show cause 

### why the mandamus relief should not 

### issue. See La. Code Civ. P. art. 

### 3865. Although set for a show cause 

## hearing, the matter was stayed. The matter 

### is remanded and the trial court 

### is 

# instructedtoconductthe showcause hearingonthepetitionfor mandamus. PMC JEW CHH

COURT OF APPEAL, FIRST CIRCUIT

EPUTY L RK OF COURT FOR THE COURT
##### 



Exhibit 32.1 CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Champion Enterprises, Inc. (the
Company) on Form 10-Q for the period ending October 2, 2004 as filed with the
Securities and Exchange Commission on the date hereof (the Report), we,
William C. Griffiths, Chief Executive Officer of the Company, and Phyllis A.
Knight, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:  (1)
    
    The Report fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)
    
    The information contained in the Report fairly presents, in
all material respects, the financial condition and results of
operations of the Company. /s/ WILLIAM C. GRIFFITHSWilliam C. GriffithsChief Executive OfficerChampion Enterprises, Inc.October 25, 2004
 /s/ PHYLLIS A. KNIGHTPhyllis A. KnightChief Financial OfficerChampion Enterprises, Inc.October 25, 2004
##### 



EXHIBIT 23.1

Consent of Independent Accountants

To Board of Directors
Front Range Capital Corporation

We consent to the use in the Form 10-QSB of Front Range Capital
Corporation for the quarterly period ended September 30, 2003 our report dated
October 31, 2003 relating to the consolidated balance sheet of Front Range
Capital Corporation and subsidiaries as of September 30, 2003 and the related
consolidated statements of income, comprehensive income and cash flows for the
three-month period and nine-month periods then ended.

/s/ Fortner, Bayens, Levkulich & Co., P.C.

Denver, Colorado
November 13, 2003
EPA DR # 4025 

April 27, 2010
EPA DR # 4025 

April 27, 2010
Editorial Note on Part 312
Editorial Note: Nomenclature changes to part 312 appear at 69 FR 13717, Mar. 24, 2004.

§ 312.58 Inspection of sponsor's records and reports. ( a ) *FDA inspection.* A sponsor shall upon request from any properly authorized officer or employee of the Food and Drug Administration, at reasonable times, permit such officer or employee to have access to and copy and verify any records and reports relating to a clinical investigation conducted under this part. Upon written request by FDA, the sponsor shall submit the records or reports (or copies of them) to FDA. The sponsor shall discontinue shipments of the drug to any investigator who has failed to maintain or make available records or reports of the investigation as required by this part.
( b ) *Controlled substances.* If an investigational new drug is a substance listed in any schedule of the Controlled Substances Act (21 U.S.C. 801; 21 CFR part 1308), records concerning shipment, delivery, receipt, and disposition of the drug, which are required to be kept under this part or other applicable parts of this chapter shall, upon the request of a properly authorized employee of the Drug Enforcement Administration of the U.S. Department of Justice, be made available by the investigator or sponsor to whom the request is made, for inspection and copying. In addition, the sponsor shall assure that adequate precautions are taken, including storage of the investigational drug in a securely locked, substantially constructed cabinet, or other securely locked, substantially constructed enclosure, access to which is limited, to prevent theft or diversion of the substance into illegal channels of distribution.
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1443 Magnesium sulfate. ( a ) Magnesium sulfate (MgSO4·7H2O, CAS Reg. No. 10034-99-8) occurs naturally as the mineral epsomite. It is prepared by neutralization of magnesium oxide, hydroxide, or carbonate with sulfuric acid and evaporating the solution to crystallization.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 183, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as a flavor enhancer as defined in § 170.3(o)(11) of this chapter; a nutrient supplement as defined in § 170.3(o)(20) of this chapter; and a processing aid as defined in § 170.3(o)(24) of this chapter.
( 2 ) The ingredient is used in foods at levels not to exceed current good manufacturing practice.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[50 FR 13560, Apr. 5, 1985]
Office for Domestic Preparedness 

U.S. Department of Homeland Security 

Washington, DC 20531

ODP Information Bulletin 

No. 165 May 6, 2005 

TO All State Administrative Agency Heads 

 All State Administrative Agency Points of Contact 

 All State Homeland Security Directors 

 All Urban Area Core City/Core County Points of Contact 

FROM: Matt Mayer, Acting Executive Director 

SUBJECT: Updated Submission Deadlines for Tactical Interoperable Communications Plans 

On April 1, 2005, the Department of Homeland Security, Office of State and Local Government 

Coordination and Preparedness, Office for Domestic Preparedness (ODP) disseminated the Tactical 

Interoperable Communications Planning Guidance and Template, developed in coordination with the 

SAFECOM program. The FY2005 Homeland Security Grant Program (HSGP) guidance requires 

grantees to develop and test a plan to achieve tactical interoperable communications. 

The deadline for submitting these plans has been extended to May 1, 2006, based on feedback from 

state and local stakeholders. Grantees have one year from that date (i.e., until May 1, 2007) in which to 

validate the plan through an operations-based exercise. 

ODP will still host two additional one-day, regional training workshops on the Tactical Interoperable 

Communications Planning Guidance and Template in conjunction with the Office of Community 

Oriented Policing Services (COPS) Interoperable Communications Technology Program Workshop 

Series. The remaining workshops are currently scheduled as follows: 

Central Region: June 3 in Columbus, Ohio 

Eastern Region: July 14 in Charlotte, North Carolina 

Invitations for the Central and Eastern Region conferences are forthcoming. ODP will continue to make 

technical assistance available through the Interoperable Communications Technical Assistance Program. 

Additional questions on this effort should be directed to: 

• ODP’s Technical Assistance staff at TArequest@dhs.gov; 

• The ODP Preparedness Officer assigned to your state; or 

• The ODP Help Line at (800) 368-6498 or askcsid@dhs.gov.
I 

118TH CONGRESS 

2D SESSION H. R. 7321 

To amend the Federal Election Campaign Act of 1971 to modernize certain 

reporting requirements for electioneering communications, and for other 

purposes. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 13, 2024 

Mr. MORELLE (for himself, Mr. STEIL, and Mr. NEGUSE) introduced the 

following bill; which was referred to the Committee on House Administration 

A BILL 

To amend the Federal Election Campaign Act of 1971 to 

modernize certain reporting requirements for electioneering communications, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Electronic Filing of 

5 Electioneering Communication Reports Act’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7321 IH

1 SEC. 2. MODERNIZATION OF CERTAIN REPORTING RE2 QUIREMENTS FOR ELECTIONEERING COM3 MUNICATIONS. 

4 Section 304(a)(11)(A)(i) of the Federal Election 

5 Campaign Act of 1971 (52 U.S.C. 30104(a)(11)(A)(i)) is 

6 amended by inserting ‘‘or makes electioneering commu7 nications’’ after ‘‘expenditures’’. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
**Exhibit31.2**

**CERTIFICATIONS**

I, John Low, certifythat:

1. I have reviewed thisquarterly report on Form 10-Q of Enterprise Informatics Inc.;

2. Based on my knowledge,this quarterly report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, notmisleading with respect to the period covered by this quarterly report;

3. Based on my knowledge,the financial statements, and other financial information included in thisquarterly report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this quarterly report;

4. The registrant’s othercertifying officer(s) and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and have:

a) designed suchdisclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this quarterly report is being prepared;

b) evaluated theeffectiveness of the registrant’s disclosure controls and procedures andpresented in this quarterly report our conclusions about the effectiveness ofthe disclosure controls and procedures, as of the end of the period covered bythis quarterly report based on such evaluation; and

c) disclosed in thisquarterly report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and

5. The registrant’s othercertifying officer(s) and I have disclosed, based on our most recent evaluationof internal control over financial reporting, to the registrant’s auditors andthe audit committee of the registrant’s board of directors (or personsperforming the equivalent functions):

a) all significantdeficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and reportfinancial information; and

b) any fraud, whether ornot material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting
| Dated:  May 15, 2007 |
|---------------------------|
|                      |
| /s/ John W. Low           |   |   |
| John W. Low               |
|                      |
| Chief Financial  Officer  |

 

1

----
<PAGE>   1
                                                                   EXHIBIT 23(C)

              CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

We hereby consent to the incorporation by reference in this Prospectus 
Supplement dated January 22, 1999 constituting part of the Registration 
Statement on Form S-3 (No. 333-29049), as supplemented by the Prospectus dated 
June 23, 1997, of our report dated January 17, 1997, appearing on page 18 of 
Aristar, Inc.'s Annual Report on Form 10-K for the year ended December 31, 
1997. We also consent to the reference to us under the heading "Experts" in 
such Prospectus Supplement.


/s/ PRICEWATERHOUSECOOPERS LLP

PricewaterhouseCoopers LLP
Tampa, Florida
January 22, 1999
<PAGE>

                                                                      EXHIBIT 11

                                ALTRIS SOFTWARE, INC.

               STATEMENT RE COMPUTATION OF NET INCOME (LOSS) PER SHARE
                                     (Unaudited)

<TABLE>
<CAPTION>

                                                                     For the three months
                                                                        ended March 31,
                                                              ------------------------------
                                                                    1996             1995
                                                                    ----             ----
                                                                 (Restated)

<S>                                                           <C>                <C>
Net (loss) income per consolidated financial statements       $ (1,117,000)      $   225,000

Primary net (loss) income per share:
Weighted average common shares                                  18,053,000        13,741,000
Common stock equivalents:
    Common stock options                                                 -           324,000
    Common stock warrants                                                -                 -
                                                              ------------       -----------
Weighted average shares outstanding                             18,053,000        14,065,000
                                                              ------------       -----------
                                                              ------------       -----------

Fully diluted net (loss) income per share:
Weighted average common shares                                  18,053,000        13,741,000
Common stock equivalents:
    Common stock options                                                 -           324,000
    Common stock warrants                                                -                 -
                                                              ------------       -----------

Weighted average shares outstanding                             18,053,000        14,065,000
                                                              ------------       -----------
                                                              ------------       -----------
Net (loss) income per share:
    Primary                                                   $      (0.06)      $       .02
                                                              ------------       -----------
                                                              ------------       -----------
    Fully diluted                                             $      (0.06)      $       .02
                                                              ------------       -----------
                                                              ------------       -----------
</TABLE>